Relay Therapeutics (RLAY) Stock Forecast & Price Target

Compare

557 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RLAY Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Relay

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RLAY Stock 12 Month Forecast

Average Price Target

$17.40

▲(71.77% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Relay Therapeutics in the last 3 months. The average price target is $17.40 with a high forecast of $22.00 and a low forecast of $14.00. The average price target represents a 71.77% change from the last price of $10.13.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","12":"$12","23":"$23","6.5":"$6.5","17.5":"$17.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,6.5,12,17.5,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.79,10.72923076923077,11.668461538461537,12.607692307692307,13.546923076923076,14.486153846153845,15.425384615384615,16.364615384615384,17.303846153846152,18.243076923076924,19.182307692307692,20.121538461538464,21.060769230769232,{"y":22,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.79,10.375384615384615,10.96076923076923,11.546153846153846,12.131538461538462,12.716923076923077,13.302307692307691,13.887692307692307,14.473076923076922,15.058461538461538,15.643846153846154,16.229230769230767,16.814615384615383,{"y":17.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.79,10.113846153846152,10.437692307692307,10.76153846153846,11.085384615384616,11.409230769230769,11.733076923076922,12.056923076923077,12.38076923076923,12.704615384615384,13.028461538461539,13.352307692307692,13.676153846153845,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.41,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.47,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.18,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.52,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.36,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.66,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.32,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.14,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.46,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.15,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.79,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$22.00

Average Price Target$17.40

Lowest Price Target$14.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Eva Fortea Verdejo

Wells Fargo

$15→$17

Buy

67.82%

Upside

Assigned

03/17/26

Relay Therapeutics (RLAY) Receives a Buy from Wells Fargo

Silvan Tuerkcan

Citizens JMP

$15→$17

Buy

67.82%

Upside

Reiterated

03/17/26

Relay Therapeutics price target raised to $17 from $15 at CitizensRelay Therapeutics price target raised to $17 from $15 at Citizens

Bradley Canino

Guggenheim

$15→$22

Buy

117.18%

Upside

Reiterated

03/12/26

Guggenheim Sticks to Its Buy Rating for Relay Therapeutics (RLAY)

Chi Meng Fong

Bank of America Securities

―

Buy

―

Reiterated

03/12/26

Analysts Offer Insights on Healthcare Companies: Relay Therapeutics (NASDAQ: RLAY), Stryker (NYSE: SYK) and Elutia (NASDAQ: ELUT)

Matthew Biegler

Oppenheimer

$14

Buy

38.20%

Upside

Reiterated

02/27/26

Oppenheimer Remains a Buy on Relay Therapeutics (RLAY)

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

02/26/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Etzer Darout

Barclays

$17

Buy

67.82%

Upside

Reiterated

02/26/26

Barclays Remains a Buy on Relay Therapeutics (RLAY)

Robert Burns

H.C. Wainwright

$14

Buy

38.20%

Upside

Reiterated

11/10/25

Relay Therapeutics: Strong Financial Position and Promising Clinical Developments Justify Buy Rating

Andrew Berens

Leerink Partners

$12

Buy

18.46%

Upside

Reiterated

08/12/25

Relay Therapeutics (RLAY) Receives a Buy from Leerink Partners

Sean McCutcheon

Raymond James

$29→$19

Buy

87.56%

Upside

Reiterated

08/08/25

Relay Therapeutics price target lowered to $19 from $29 at Raymond JamesRelay Therapeutics price target lowered to $19 from $29 at Raymond James

Eric Joseph

J.P. Morgan

$21→$11

Buy

8.59%

Upside

Reiterated

05/13/25

Relay Therapeutics (RLAY) PT Lowered to $11 at JPMorganJPMorgan analyst Eric Joseph lowered the price target on Relay Therapeutics (NASDAQ: RLAY) to $11.00 (from $21.00) while maintaining a Overweight rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Eva Fortea Verdejo

Wells Fargo

$15→$17

Buy

67.82%

Upside

Assigned

03/17/26

Relay Therapeutics (RLAY) Receives a Buy from Wells Fargo

Silvan Tuerkcan

Citizens JMP

$15→$17

Buy

67.82%

Upside

Reiterated

03/17/26

Relay Therapeutics price target raised to $17 from $15 at CitizensRelay Therapeutics price target raised to $17 from $15 at Citizens

Bradley Canino

Guggenheim

$15→$22

Buy

117.18%

Upside

Reiterated

03/12/26

Guggenheim Sticks to Its Buy Rating for Relay Therapeutics (RLAY)

Chi Meng Fong

Bank of America Securities

―

Buy

―

Reiterated

03/12/26

Analysts Offer Insights on Healthcare Companies: Relay Therapeutics (NASDAQ: RLAY), Stryker (NYSE: SYK) and Elutia (NASDAQ: ELUT)

Matthew Biegler

Oppenheimer

$14

Buy

38.20%

Upside

Reiterated

02/27/26

Oppenheimer Remains a Buy on Relay Therapeutics (RLAY)

Yaron Werber

TD Cowen

―

Buy

―

Reiterated

02/26/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Etzer Darout

Barclays

$17

Buy

67.82%

Upside

Reiterated

02/26/26

Barclays Remains a Buy on Relay Therapeutics (RLAY)

Robert Burns

H.C. Wainwright

$14

Buy

38.20%

Upside

Reiterated

11/10/25

Relay Therapeutics: Strong Financial Position and Promising Clinical Developments Justify Buy Rating

Andrew Berens

Leerink Partners

$12

Buy

18.46%

Upside

Reiterated

08/12/25

Relay Therapeutics (RLAY) Receives a Buy from Leerink Partners

Sean McCutcheon

Raymond James

$29→$19

Buy

87.56%

Upside

Reiterated

08/08/25

Relay Therapeutics price target lowered to $19 from $29 at Raymond JamesRelay Therapeutics price target lowered to $19 from $29 at Raymond James

Eric Joseph

J.P. Morgan

$21→$11

Buy

8.59%

Upside

Reiterated

05/13/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Relay Therapeutics

3 Months

xxx

Success Rate

7/14 ratings generated profit

Average Return

+2.51%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +2.51% per trade.

1 Year

Andrew BerensLeerink Partners

Success Rate

6/11 ratings generated profit

Average Return

+79.55%

a rating ―

Copying Andrew Berens's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +79.55% per trade.

2 Years

xxx

Success Rate

11/11 ratings generated profit

Average Return

+132.26%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +132.26% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RLAY Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RLAY has received 9 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. RLAY average Analyst price target in the past 3 months is 17.40.

Each month's total comprises the sum of three months' worth of ratings.

RLAY Financial Forecast

RLAY Earnings Forecast

Next quarter’s earnings estimate for RLAY is -$0.36 with a range of -$0.45 to -$0.20. The previous quarter’s EPS was -$0.32. RLAY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year RLAY has Performed in-line its overall industry.

RLAY Sales Forecast

Next quarter’s sales forecast for RLAY is $4.83M with a range of $0.00 to $30.20M. The previous quarter’s sales results were $7.00M. RLAY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year RLAY has Performed in-line its overall industry.

RLAY Stock Forecast FAQ

What is RLAY’s average 12-month price target, according to analysts?

Based on analyst ratings, Relay Therapeutics’s 12-month average price target is 17.40.

What is RLAY’s upside potential, based on the analysts’ average price target?

Relay Therapeutics has 71.77% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RLAY a Buy, Sell or Hold?

Relay Therapeutics has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is Relay Therapeutics’s price target?

The average price target for Relay Therapeutics is 17.40. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $22.00 ,the lowest forecast is $14.00. The average price target represents 71.77% Increase from the current price of $10.13.

What do analysts say about Relay Therapeutics?

Relay Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of RLAY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Relay Therapeutics (RLAY) Stock Forecast & Price Target

RLAY Analyst Ratings

RLAY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Relay Therapeutics

RLAY Analyst Recommendation Trends

RLAY Financial Forecast

RLAY Earnings Forecast

RLAY Sales Forecast

RLAY Stock Forecast FAQ

Detailed List of Analyst Forecasts